1 / 53

Patient Case 1

Patient Case 1. Patient Case 1: PET/CT Scan. Patient Case 1: Disease Stage. Techniques for Diagnosis of Lung Cancer. Use of EBUS Cytologic Material for Molecular Diagnosis of Lung Cancer. Histology in NSCLC. Lung Cancer Pathology: Non-Small Cell Carcinoma and Small Tissue Specimens.

tyler-hopkins
Télécharger la présentation

Patient Case 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Patient Case 1

  2. Patient Case 1: PET/CT Scan

  3. Patient Case 1: Disease Stage

  4. Techniques for Diagnosis of Lung Cancer

  5. Use of EBUS Cytologic Material for Molecular Diagnosis of Lung Cancer

  6. Histology in NSCLC

  7. Lung Cancer Pathology: Non-Small Cell Carcinoma and Small Tissue Specimens

  8. EBUS and Genotyping: Navani Study

  9. EBUS and Genotyping: Navani Study (cont)

  10. Cisplatin/Pemetrexed vs Cisplatin/ Gemcitabine: First-line Therapy

  11. Patient Case 1: Treatment

  12. Patient Case 1: Maintenance or Not?

  13. IFCT-GFPC 0502: Gemcitabine vs Erlotinib vs Observation as Maintenance

  14. IFCT-GFPC 0502: Treatment Outcomes

  15. SATURN Trial: PFS and OS for All Patients (ITT)

  16. SATURN Trial: PFS and OS by Induction Response

  17. Patient Case 1: Progression

  18. Forest Plot of Survival by Subsets

  19. Types of Gene Mutation Assays

  20. Positions of Mutations Detected in EGFR Tyrosine Kinase Domain in NSCLC

  21. Tyrosine Kinase Inhibitors

  22. Compilation of EGFR TKI Studies

  23. IPASS Study: Prospective Clinical Selection/Retrospective Molecular Selection

  24. Objective Response Rate in Patients Positive and Negative for EGFR Mutation

  25. Comparison of PFS by Mutation Status Within Treatment Arms

  26. HRQoL and Symptom Improvement by EGFR Mutation Status (EFQ)

  27. Patient Case 2: Progression

  28. Patient Case 2: Treatment

  29. Patient Treated With Gefitinib for Exon 19 Mutation-Positive Lung Cancer Since 2005

  30. Patient Case 2: Progression (cont)

  31. Patient Case 2: Treatment (cont)

  32. Importance of Working Together

  33. Thank you for participatingin this activity.

More Related